{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:31:22Z","timestamp":1791955882321,"version":"4.3.4"},"reference-count":16,"publisher":"BMJ","issue":"1","funder":[{"name":"Merck KGaA, Darmstadt, Germany"},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-017-0310-x","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T08:49:12Z","timestamp":1516092552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":297,"title":["Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u22651\u00a0year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial"],"prefix":"10.1136","volume":"6","author":[{"given":"Howard L.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery S.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Terheyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent C.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Brownell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen H.","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"von Heydebreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meliessa","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"issue":"16","key":"310_CR1","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.ejca.2015.06.131","volume":"51","author":"C Lebbe","year":"2015","unstructured":"Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51(16):2396\u2013403.","journal-title":"Eur J Cancer"},{"key":"310_CR2","doi-asserted-by":"crossref","unstructured":"Terheyden P, Becker JC. New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. 2017; March 9. [Epub ahead of print]","DOI":"10.1097\/CCO.0000000000000363"},{"key":"310_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","volume":"71","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D, Lebbe C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53\u201369.","journal-title":"Eur J Cancer"},{"issue":"10","key":"310_CR4","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1200\/JCO.2005.02.329","volume":"23","author":"PJ Allen","year":"2005","unstructured":"Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300\u20139.","journal-title":"J Clin Oncol"},{"key":"310_CR5","series-title":"Version I","volume-title":"Clinical practice guidelines in oncology: Merkel cell carcinoma","author":"NCCN","year":"2018","unstructured":"NCCN Clinical practice guidelines in oncology: Merkel cell carcinoma. Version I.2018."},{"issue":"14","key":"310_CR6","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2217\/fon-2017-0072","volume":"13","author":"P Nghiem","year":"2017","unstructured":"Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13(14):1263\u201379.","journal-title":"Future Oncol"},{"issue":"26","key":"310_CR7","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"10","key":"310_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"key":"310_CR9","doi-asserted-by":"publisher","unstructured":"Topalian SL, Bhatia S, Hollebecque A, Awada A, De Boer JP, Kudchadkar RR, et al. Non-comparative, open-label, multiple cohort, phase 1\/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res 2017;77(Suppl 13 [Abstract CT074]). doi:\n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT074\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2017-CT074"},{"key":"310_CR10","volume-title":"(avelumab) injection [package insert]","author":"Bavencio","year":"2017","unstructured":"Bavencio. (avelumab) injection [package insert]. Darmstadt: Merck KGaA; 2017."},{"issue":"2","key":"310_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"310_CR12","doi-asserted-by":"publisher","unstructured":"Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Durable responses to avelumab (anti\u2013PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update. Cancer Res 2017;77(Suppl 13 [Abstract CT079]). doi:\n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT074\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2017-CT074"},{"issue":"19","key":"310_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2217\/fon-2017-0187","volume":"13","author":"CL Cowey","year":"2017","unstructured":"Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world outcomes of patients with metastatic Merkel cell caricnoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699\u2013710.","journal-title":"Future Oncol"},{"key":"310_CR14","doi-asserted-by":"publisher","unstructured":"Becker J, Lorenz E, Haas G, Helwig C, Oksen D, Mahnke L, et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann Oncol 2016;26(Suppl 3 [Abstract 2602]). doi:\n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2017-CT074\n                    \n                  .","DOI":"10.1158\/1538-7445.AM2017-CT074"},{"issue":"9","key":"310_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"},{"key":"310_CR16","doi-asserted-by":"publisher","unstructured":"Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, et al. Immune evasion mechanisms and immune checkpoint inhibition in advanced Merkel cell carcinoma. OncoImmunology. 2017; \n                    https:\/\/doi.org\/10.1080\/2162402X.2017.1338237\n                    \n                  .","DOI":"10.1080\/2162402X.2017.1338237"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0310-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:43:46Z","timestamp":1601041426000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0310-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["310"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0310-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]},"assertion":[{"value":"26 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, institutional review board approvals, and institutional safety monitoring. Written informed consent was provided.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HLK reports consultancy for and honoraria from Amgen, Celldex, Compass Therapeutics, EMD Serono, Prometheus, Sanofi, Turnstone Biologics, and Merck KGaA, Darmstadt, Germany; reports research funding from Amgen, EMD Serono, Prometheus, Viralytics, and Merck KGaA, Darmstadt, Germany; and is a member of a speaker\u2019s bureau for Merck KGaA, Darmstadt, Germany. JSR reports consultancy for EMD Serono. OH reports consultancy for Amgen, Novartis, Roche, Bristol-Myers Squibb, and Merck KGaA, Darmstadt, Germany; is a member of a speaker\u2019s bureau for Bristol-Myers Squibb, Genentech, Novartis, and Amgen; and has received research funding from Astra Zeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Incyte, Merck KGaA, Darmstadt, Germany, Merck Serano, MedImmune, Novartis, Pfizer, Rinat and Roche. SB received research support from EMD Serono. PT has received reimbursement and non-financial support from other commercial sponsors, outside the submitted work. SPD reports employment at Memorial Sloan Kettering Cancer Center and is a member of advisory boards for EMD Serrano, Nektar, and Amgen. CL reports advisory and consultancy for Roche, Bristol-Myers Squibb, Novartis, Amgen, GlaxoSmithKline, and Merck, Sharpe, and Dohme; has received research support from Roche and Bristol-Myers Squibb; is a member of a speaker\u2019s bureau for Bristol-Myers Squibb, Amgen, Roche, and Novartis; has received honoraria from Roche, Bristol-Myers Squibb, Novartis, Amgen, and Merck, Sharpe, and Dohme; and has received travel accommodations from Roche, Bristol-Myers Squibb, and Novartis. KDL has received research support from EMD Serono. JHL has received research support from Novartis, Takeda-Millennium, and Bristol-Myers Squibb; and is a member of an advisory board for Bristol-Myers Squibb and Eisai. AvH reports employment at and is a stock shareholder of Merck KGaA, Darmstadt, Germany. MH reports employment at EMD Serono. PN has received research support from EMD Serono and Bristol-Myers Squibb; and has received personal fees from EMD Serono and Pfizer outside the submitted work. The remaining authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"7"}}